Latest Breaking News On - மீட்டெடுப்பு அமைப்பு - Page 1 : vimarsana.com

Assets expand immunology portfolio to include B-cell therapy and macrophage modulation - - IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 20222023 - Aurinia Pharmaceuticals Inc. today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. “Over the past year, in anticipation of .

United statesUnited kingdomNeil solomonsRob huizingaGlenn schulmanPeter greenleafAurinia pharmaceuticals incExchange commission electronic document gatheringDrug administrationRiptide bioscience incThunderbolt pharma incInvestor relations corporate communicationsChief executive officerRecombinant fc protein targetingThunderbolt pharmaB cell activating factor